Download
  Back
2011/07/26 6:00 PM

New promising data in the phase I/II clinical trial in Lupus patients: Data from the last cohort of patients (240 mcg) confirm the safety, immunogenicity and pharmacodynamic of IFN-K

Information only available in PDF version.

This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: ym1rlsZnl5mUlW6fZ8Znl2Flm2pix5HHa2THxJZvap+baW5oyGyWmMXLZm9onmtv
- Check this key: https://www.security-master-key.com.
  Download
  Back

Each PDF has been scanned by antimalware and incorporates a SECURITY MASTER Footprint. To check its authenticity:
www.security-master-footprint.com

Party powered automatically by Actusnews Wire ©
(Primary Information Provider)